GALDERMA
Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation roadmap.
The license updates, issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on RelabotulinumtoxinA (QM1114). One of Galderma’s key innovation pipeline assets in Injectable Aesthetics, RelabotulinumtoxinA is a next-generation liquid neuromodulator in Injectable Aesthetics developed using Galderma’s proprietary PEARL™ technology. This technology preserves the molecule’s integrity, resulting in a highly active, complex-free botulinum toxin A.
“Our commitment to leading innovation in dermatology is reflected in our high-performance operations. These new license updates granted by the Swedish authorities reflect Galderma’s skills and the capacities we are building to support our rapid growth trajectory. As we work to extend our category leadership globally, these new capabilities will increase Galderma’s autonomy to manufacture and commercialize the next generation of scientifically differentiated innovations in dermatology.”
ADRIAN MURPHY HEAD OF GLOBAL OPERATIONS GALDERMA
|
Galderma’s center of excellence in Uppsala is one of the company’s four state-of-the-art manufacturing and R&D facilities around the world. Galderma is currently expanding this site in response to growing global demand for science-based premium dermatology solutions. The new facility—scheduled for completion by the end of 2025—will be strategically positioned to cater to the higher demand for injectable aesthetics treatments worldwide and the development of upcoming products. With a modular design that allows for seamless further expansion in the future, this forward-looking approach aligns with both Galderma’s growth strategy and its environment, social and governance (ESG) roadmap.
About RelabotulinumtoxinA (QM1114)
Developed by Galderma, RelabotulinumtoxinA is a highly active, innovative, complex-free and ready-to-use liquid botulinum toxin A with a proprietary strain. Manufactured using a unique state-of-the-art process, it is designed as a liquid. This avoids the need to reconstitute from powder and thus eliminates the variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally, with a view to expanding its neuromodulator portfolio – part of the broadest injectable aesthetics portfolio on the market.
About Galderma
Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618347979/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 202515.10.2025 22:57:00 CEST | Press release
15 abstracts spanning advancements in early detection of recurrence, tumor profiling, and therapy response monitoringPresentations highlight the power of Guardant Health’s blood-based assays to reduce treatment burden and improve disease monitoring across multiple cancer types Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented in 15 accepted abstracts at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. These presentations span the cancer care treatment continuum, from minimal residual disease (MRD) detection and recurrence monitoring to advanced-stage tumor profiling and therapy response assessment. Guardant Health’s accepted abstracts span multiple tumor types, including lung, colorectal, breast, head and neck, and cancers of unknown primary. Together, they underscore the company’s commitment to harnessing cutting-edge
Greenland Resources Signs Mandate Agreement With European Bank15.10.2025 21:06:00 CEST | Press release
Greenland Resources A/S, a fully owned Greenlandic subsidiary of Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) (“Greenland Resources” or the “Company”) is pleased to announce the Company has signed a mandate letter with a major German Bank (the “Bank”) to act as the Export Credit Agency (“ECA”) Coordinator for the Project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015159644/en/ The ECA Coordinator role covers the relevant tasks up to debt financial close. The Bank has extensive experience in acting as the ECAs Coordinator in project financings worldwide, as well as being one of Europe’s most prestigious institutions. The Bank will now be in a position to start working with some of the ECA’s discussed in previous press releases (primarily EKN, Finnvera, and EIFO). The Company’s debt part of the Capex is around US$750 million. Mandating the Bank complements the Company’s strategy to increase EU and specifically
Interactive Brokers Launches Ask IBKR: AI Tool Delivers Instant Portfolio Answers15.10.2025 16:00:00 CEST | Press release
New Natural Language Interface Helps Clients Analyze Holdings, Performance, and Allocation in Seconds Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Ask IBKR, an AI-powered tool that delivers instant portfolio insights through natural language queries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015991473/en/ “With Ask IBKR, we’re introducing a natural language-based way for investors to interact with their portfolio data,” said Milan Galik, Chief Executive Officer at Interactive Brokers. “Instead of navigating across screens, clients can simply ask, ‘What sector am I underweight compared to the S&P 500?’ and get an instant, visualized answer.” Categories of queries include: Portfolio Metrics: Compare performance against benchmarks, identify valuation changes over time, and highlight periods of outperformance or underperformance Allocation Analysis: Analyze sect
Multiply Group Announces Plans to Acquire 2PointZero and Ghitha Holding via Share Swap15.10.2025 15:36:00 CEST | Press release
The proposed acquisition forms part of Multiply Group’s broader strategy to build scale, enhance portfolio synergies, and drive long-term value.2PointZero brings scalable assets across energy, mining and financial services, while Ghitha Holding contributes a diversified food and agriculture platform.The transaction remains subject to shareholder and regulatory approvals, with further details to be announced upon completion of the review process. Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company that invests in and operates businesses globally, today announced that its Board has approved a proposal to acquire 2PointZero and Ghitha Holding through a share swap transaction. Under the proposed terms, Multiply Group would offer shares to acquire 2PointZero and Ghitha Holding, followed by the issuance of new shares to complete the transaction. The transaction is currently under review and remains subject to shareholder and regulatory approvals. 2PointZero is a tr
Svante Hails Nobel Prize in Chemistry, Validating Metal-Organic Framework Technology is Critical for Commercial Carbon Capture15.10.2025 15:30:00 CEST | Press release
The Nobel Prize for Chemistry has awarded scientists for their work in metal-organic frameworks (MOFs), for their high capacity and selectivity for captured gases, including CO2. The CALF-20 MOF used in Svante’s filters for carbon capture and removal, was highlighted in the award announcement. Svante, a leader in solid sorbent-based carbon capture and removal filter technology, celebrated the announcement of the 2025 Nobel Prize in Chemistry last week, which honored scientists Susumu Kitagawa, Richard Robson and Omar Yaghi for their groundbreaking work in the metal-organic framework (MOF) field. The Royal Swedish Academy of Sciences awarded the prize for the development of MOFs, citing their "enormous potential" and unique molecular architecture that creates spacious, porous materials capable of capturing and storing specific substances, including carbon dioxide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015855374/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom